352 related articles for article (PubMed ID: 20664527)
1. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.
Koski A; Kangasniemi L; Escutenaire S; Pesonen S; Cerullo V; Diaconu I; Nokisalmi P; Raki M; Rajecki M; Guse K; Ranki T; Oksanen M; Holm SL; Haavisto E; Karioja-Kallio A; Laasonen L; Partanen K; Ugolini M; Helminen A; Karli E; Hannuksela P; Pesonen S; Joensuu T; Kanerva A; Hemminki A
Mol Ther; 2010 Oct; 18(10):1874-84. PubMed ID: 20664527
[TBL] [Abstract][Full Text] [Related]
2. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.
Pesonen S; Diaconu I; Cerullo V; Escutenaire S; Raki M; Kangasniemi L; Nokisalmi P; Dotti G; Guse K; Laasonen L; Partanen K; Karli E; Haavisto E; Oksanen M; Karioja-Kallio A; Hannuksela P; Holm SL; Kauppinen S; Joensuu T; Kanerva A; Hemminki A
Int J Cancer; 2012 Apr; 130(8):1937-47. PubMed ID: 21630267
[TBL] [Abstract][Full Text] [Related]
3. Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans.
Bramante S; Koski A; Kipar A; Diaconu I; Liikanen I; Hemminki O; Vassilev L; Parviainen S; Cerullo V; Pesonen SK; Oksanen M; Heiskanen R; Rouvinen-Lagerström N; Merisalo-Soikkeli M; Hakonen T; Joensuu T; Kanerva A; Pesonen S; Hemminki A
Int J Cancer; 2014 Aug; 135(3):720-30. PubMed ID: 24374597
[TBL] [Abstract][Full Text] [Related]
4. Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans.
Bramante S; Kaufmann JK; Veckman V; Liikanen I; Nettelbeck DM; Hemminki O; Vassilev L; Cerullo V; Oksanen M; Heiskanen R; Joensuu T; Kanerva A; Pesonen S; Matikainen S; Vähä-Koskela M; Koski A; Hemminki A
Int J Cancer; 2015 Oct; 137(7):1775-83. PubMed ID: 25821063
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients.
Cerullo V; Pesonen S; Diaconu I; Escutenaire S; Arstila PT; Ugolini M; Nokisalmi P; Raki M; Laasonen L; Särkioja M; Rajecki M; Kangasniemi L; Guse K; Helminen A; Ahtiainen L; Ristimäki A; Räisänen-Sokolowski A; Haavisto E; Oksanen M; Karli E; Karioja-Kallio A; Holm SL; Kouri M; Joensuu T; Kanerva A; Hemminki A
Cancer Res; 2010 Jun; 70(11):4297-309. PubMed ID: 20484030
[TBL] [Abstract][Full Text] [Related]
6. Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy.
Hemminki O; Parviainen S; Juhila J; Turkki R; Linder N; Lundin J; Kankainen M; Ristimäki A; Koski A; Liikanen I; Oksanen M; Nettelbeck DM; Kairemo K; Partanen K; Joensuu T; Kanerva A; Hemminki A
Oncotarget; 2015 Feb; 6(6):4467-81. PubMed ID: 25714011
[TBL] [Abstract][Full Text] [Related]
7. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus.
Kanerva A; Nokisalmi P; Diaconu I; Koski A; Cerullo V; Liikanen I; Tähtinen S; Oksanen M; Heiskanen R; Pesonen S; Joensuu T; Alanko T; Partanen K; Laasonen L; Kairemo K; Pesonen S; Kangasniemi L; Hemminki A
Clin Cancer Res; 2013 May; 19(10):2734-44. PubMed ID: 23493351
[TBL] [Abstract][Full Text] [Related]
8. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus.
Cerullo V; Diaconu I; Kangasniemi L; Rajecki M; Escutenaire S; Koski A; Romano V; Rouvinen N; Tuuminen T; Laasonen L; Partanen K; Kauppinen S; Joensuu T; Oksanen M; Holm SL; Haavisto E; Karioja-Kallio A; Kanerva A; Pesonen S; Arstila PT; Hemminki A
Mol Ther; 2011 Sep; 19(9):1737-46. PubMed ID: 21673660
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers.
Du T; Shi G; Li YM; Zhang JF; Tian HW; Wei YQ; Deng H; Yu DC
Cancer Gene Ther; 2014 Aug; 21(8):340-8. PubMed ID: 25034886
[TBL] [Abstract][Full Text] [Related]
10. An Oncolytic Adenovirus Encoding Decorin and Granulocyte Macrophage Colony Stimulating Factor Inhibits Tumor Growth in a Colorectal Tumor Model by Targeting Pro-Tumorigenic Signals and via Immune Activation.
Liu Z; Yang Y; Zhang X; Wang H; Xu W; Wang H; Xiao F; Bai Z; Yao H; Ma X; Jin L; Wu C; Seth P; Zhang Z; Wang L
Hum Gene Ther; 2017 Aug; 28(8):667-680. PubMed ID: 28530155
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.
Liikanen I; Ahtiainen L; Hirvinen ML; Bramante S; Cerullo V; Nokisalmi P; Hemminki O; Diaconu I; Pesonen S; Koski A; Kangasniemi L; Pesonen SK; Oksanen M; Laasonen L; Partanen K; Joensuu T; Zhao F; Kanerva A; Hemminki A
Mol Ther; 2013 Jun; 21(6):1212-23. PubMed ID: 23546299
[TBL] [Abstract][Full Text] [Related]
12. Immunological effects of a tumor necrosis factor alpha-armed oncolytic adenovirus.
Hirvinen M; Rajecki M; Kapanen M; Parviainen S; Rouvinen-Lagerström N; Diaconu I; Nokisalmi P; Tenhunen M; Hemminki A; Cerullo V
Hum Gene Ther; 2015 Mar; 26(3):134-44. PubMed ID: 25557131
[TBL] [Abstract][Full Text] [Related]
13. Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer.
Hemminki O; Diaconu I; Cerullo V; Pesonen SK; Kanerva A; Joensuu T; Kairemo K; Laasonen L; Partanen K; Kangasniemi L; Lieber A; Pesonen S; Hemminki A
Mol Ther; 2012 Sep; 20(9):1821-30. PubMed ID: 22871667
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor efficacy of a novel fiber chimeric oncolytic adenovirus expressing p53 on hepatocellular carcinoma.
Chen W; Wu Y; Liu W; Wang G; Wang X; Yang Y; Chen W; Tai Y; Lu M; Qian Q; Zhang Q; Chen G
Cancer Lett; 2011 Aug; 307(1):93-103. PubMed ID: 21504839
[TBL] [Abstract][Full Text] [Related]
15. Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model.
Kuryk L; Haavisto E; Garofalo M; Capasso C; Hirvinen M; Pesonen S; Ranki T; Vassilev L; Cerullo V
Int J Cancer; 2016 Oct; 139(8):1883-93. PubMed ID: 27287512
[TBL] [Abstract][Full Text] [Related]
16. A Bicistronic Adenoviral Vector Carrying Cytosine Deaminase and Granulocyte-Macrophage Colony-Stimulating Factor Increases the Therapeutic Efficacy of Cancer Gene Therapy.
Akbulut H; Coleri A; Sahin G; Tang Y; Icli F
Hum Gene Ther; 2019 Aug; 30(8):999-1007. PubMed ID: 30892086
[TBL] [Abstract][Full Text] [Related]
17. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
[TBL] [Abstract][Full Text] [Related]
18. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.
Ranki T; Kanerva A; Ristimäki A; Hakkarainen T; Särkioja M; Kangasniemi L; Raki M; Laakkonen P; Goodison S; Hemminki A
Gene Ther; 2007 Jan; 14(1):58-67. PubMed ID: 16900223
[TBL] [Abstract][Full Text] [Related]
19. A mosaic fiber adenovirus serotype 5 vector containing reovirus sigma 1 and adenovirus serotype 3 knob fibers increases transduction in an ovarian cancer ex vivo system via a coxsackie and adenovirus receptor-independent pathway.
Tsuruta Y; Pereboeva L; Glasgow JN; Rein DT; Kawakami Y; Alvarez RD; Rocconi RP; Siegal GP; Dent P; Fisher PB; Curiel DT
Clin Cancer Res; 2007 May; 13(9):2777-83. PubMed ID: 17473211
[TBL] [Abstract][Full Text] [Related]
20. Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy.
Kochneva G; Sivolobova G; Tkacheva A; Grazhdantseva A; Troitskaya O; Nushtaeva A; Tkachenko A; Kuligina E; Richter V; Koval O
Oncotarget; 2016 Nov; 7(45):74171-74188. PubMed ID: 27708236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
